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V2 Receptor Antagonist; Tolvaptan
Review
Hyponatremia is the most common electrolyte disorder in hospitalized patients. 
Many studies documented that it was related to increased morbidity and mortality 
in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. 
Although knowledge of hyponatremia has been cumulated, the optimal manage­
ment of hyponatremia remains incompletely established in clinical practice because 
of the diversity of underlying disease states, and its multiple causes with differing 
pathophysiologic mechanisms. Since vasopressin receptor antagonists have 
unique aquaretic effect to selectively increase electrolytes­free water excretion, 
clinicians could apply a more effective method to treat hyponatremia. Tolvaptan 
has significant evidence that it improves serum sodium levels in patients with 
euvolemic or hypervolemic hyponatremia related with heart failure, cirrhosis 
or syndrome of inappropriate anti­diuretic hormone. Tolvaptan has acceptable 
safety and tolerability for long­term usage in chronic hyponatremia, and the 
beneficial effects on serum Na
+ occurred in patients with both mild and marked 
hyponatremia.
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receptor antagonists that are orally and intravenously active. 
Orally active vaptans, compared to intravenous use, are more 
convenient and similarly effective. This article reviews the 
various types and functions of vasopressin receptors and the 
therapeutic role of tolvaptan in clinical conditions.
Arginine Vasopressin (AVP)
AVP is a neuropeptide hormone synthesized in the para­
ventricular nuclei and supraoptic nuclei of the hypothalamus, 
and stored in the posterior pituitary
7). Normally, its secretion 
is strongly influenced by small changes, as little as 1%, in 
plasma osmolality detected by osmoreceptors in the hypo­
thalamus
7). Thus, this process results in fine control of 
serum sodium levels and serum osmolality
7). Also, AVP 
Introduction
Hyponatremia is the most common electrolyte disorder 
in hospitalized patients
1, 2). Many studies documented that 
it is related to increased morbidity and mortality in patients 
with congestive heart failure, liver cirrhosis, and neurologic 
diseases
3­6). Although knowledge of hyponatremia has 
accumulated, the optimal management of hyponatremia 
remains incomplete in clinical practice because of the diversity 
of underlying disease states, and its multiple causes with 
differing pathophysiologic mechanisms. Since vasopressin 
receptor antagonists have unique aquaretic effect to selectively 
increase electrolytes­free water excretion, clinicians could 
apply a more effective method to treat hyponatremia.
The vaptans are non­peptide arginine­vasopressin­
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release is stimulated by a decrease in blood volume through 
baroreceptors in the carotid artery, aortic arch and left atrium, 
which sense changes in intra­arterial plasma volume. AVP 
levels were unsuitably increased in several clinical settings, 
such as heart failure, liver cirrhosis, synd  rome of inappro­
priate anti­diuretic hormone (SIADH), and surgical stress
8).
Arginine Vasopressin Receptors
1. V1a Receptors 
Vascular smooth muscle cells (in the myocardium), hepa­
tocytes and platelets have V1a receptors that are activated by 
AVP or agonists, and lead to vasoconstriction in the coronary, 
peripheral circulation, and platelet aggregation
9). Also, 
activated V1a receptors cause an increase in intracellular 
calcium levels in cardiac myocytes and protein synthesis. 
V1a receptors are activated by a phosphoinositol signaling 
pathway.
2. V1b Receptors
V1b receptors are found in the anterior pituitary and have 
functions related to adrenocorticotropic hormone release
10). 
However the role of these receptors has not been found, yet. 
The V1b receptors, like the V1a receptors, use a phosphoinositol 
signaling pathway
10).
3. V2 Receptors
The V2 receptors are located on the collecting tubules of 
the kidney and have functions related to free water absorption 
by activating the aquaporin­2 channel on the apical plasma 
membrane of the collecting duct cells
11). Such antidiuretic 
function occurs through the adenylate cyclase signaling 
pathway with intracellular cyclic adenosine monophosphate 
as a second messenger, in the collecting duct cells
9, 11). 
Vasopressin Receptor Antagonists (VRAs)
Although AVP receptor antagonists were the first 
developed peptide antagonists in the 1960s and although 
animal studies showed that these peptides had an anti­
diuretic effect, several limitations of clinical use were found. 
These peptides mediate a paradoxical weak agonism to the 
V2 receptor and were seen in human studies to have poor 
oral bioavailability and short biological half lives
9).
In 1992, the non­peptide V2 antagonist was first deve­
loped by Yamamura et al
12). These non­peptide VRAs had 
more bioavailability and longer half lives than the peptide 
types. Several non­peptide VRAs, including conivaptan, 
tolvaptan, lixivaptan, relcovaptan (SR­49059) and satavaptan, 
have been studied in human clinical trials which could be 
administrated through oral or intravenous route and were 
all derived from benzazepine or oxindole derivatives. They 
have relatively different selectivity for the various AVP re­
ceptor subtypes.
Tolvaptan
Tolvaptan is an orally active, non­peptide, selective V2 
receptor antagonist
13). It has about 2 times greater affinity 
for the V2 receptor than native AVP and a 29­fold greater 
selectivity for the V2 receptors than the V1a re  ceptors
13, 14). It 
is not related to V1b receptors and also its metabolites have 
no activity at the V2 receptor
13). The effect of tolvaptan is to 
increase urine free water excretion causing decreased urine 
osmolality, and increased Na
+ concentration. 
1. Pharmacokinetics
Following oral administration of tolvaptan, at least 40% 
of an oral dose is absorbed; highly protein bound (99%), and 
reaches peak concentrations in 2 to 4 hours without any effects 
from food
13). Its terminal phase half­life is 12 hours. CYP450 
isoenzyme plays a role in its metabolism and its elimination 
is mainly non­renal. Moderate­to­severe hepatic impairment 
or congestive heart failure decreases the clearance and 52      Yi JH et al. • V2 Receptor Antagonist; Tolvaptan
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increases the volume of distribution, respectively
13­15). Patients 
with chronic kidney disease (creatinine clearance < 10 mL/
min) and dialysis were not studied. The onset of free water 
diuresis and serum Na
+ increase is about 2 to 4 hours after 
administration, in addition to the peak effect for diuresis and 
serum Na
+, which is within 4 to 8 hours. At 24 hours, about 
60% of the peak effect on Na
+ is maintained. Doses >60 mg/
day do not increase the peak effect
13­15).
2. Clinical Trials
Tolvaptan was evaluated in 2 identical multicenter, ran­
domized, double­blinded, placebo­controlled studies en  rolling 
448 patients with euvolemic or hypervolemic hyponatremia, 
as titiled, Study of Ascending Levels of Tolvaptan in 
Hyponatremia (SALT­1 and ­2)
16). In SALT­1 and ­2 studies, 
patients were randomly assigned to receive tolvaptan at 15 
mg for 30 days once daily titrated up to 60 mg if needed, or 
placebo for 30 days once daily. Eligible patients were 18 years 
and older with euvolemic and hypervolemic hyponatremia 
(defined as a serum Na
+ < 135 mEq/L) of congestive heart 
failure, liver cirrhosis, and SIADH. Ineligible diseases and 
conditions of patients were hypovolemic hyponatremia, 
pychogenic polydipsia, head trauma, postoperative conditions, 
uncontrolled hypothyroidism, adrenal insufficiency, and 
medication­induced hyponatremia were excluded. Other 
exclusion criteria included the presence of ventricular 
arrhythmias, systolic blood pressure < 90 mmHg, serum 
creatinine > 3.5, Child­Pugh score > 10, serum Na
+ < 120 
mEq/L, uncontrolled diabetes, or other neurologic diseases. 
Patients were allowed to continue conventional therapy of 
heart failure (even diuretics), and if the Na
+ rose > 145 or 
> 12 mEq/L within 24 hours, the next dose of tolvaptan 
was stopped or decreased, or the investigators allowed the 
subjects to increase fluid intake. The increase in the average 
daily area under the curve (AUC) for the Na
+ concentration 
was significantly higher in the tolvaptan group than in the 
placebo group from baseline to study day 4, and day 30 (P < 
0.001). In subgroup analysis categorized to mild hyponatremia 
(130 to 135 mEq/L) or marked hyponatremia (< 130 mEq/
L) at baseline, the tolvaptan group showed a significantly 
greater increase in the average daily AUC for the serum Na
+ 
concentration (P < 0.001). Within 8 hours after the first 
administration of tolvaptan, the serum Na
+ concentrations 
were significantly higher in the tolvaptan group than in the 
placebo group for both the total patient population and the 
subgroups categorized to degree of hyponatremia at baseline 
(all P < 0.01). Significantly more patients in the tolvaptan­
treated group had normal Na
+ values at 30 days than placebo 
(P < 0.001). Urine output was significantly greater in the 
tolvaptan groups in both studies (P < 0.001). The most 
common adverse events were thirst and dry mouth, and other 
adverse events included dizziness, hypotension, acute renal 
failure, sepsis, and ascites. After discontinuation of treatment, 
patients’ Na
+ values decreased in both the tolvaptan and 
placebo groups and there was no statistical difference.
The long term use of tolvaptan in chronic hyponatremia 
was assessed in The Safety and sodium Assessment of Long­
term Tolvaptan With hyponatremia: A year­long, open­
label Trial to gain Experience under Real­world conditions 
(SALTWATER) study
17). The SALTWATER study was an 
international, multicenter, nonrandomized, open­label exten­
sion of SALT­1 and ­2 studies. In total, 111 patients with 
hyponatremia received oral tolvaptan for a mean follow­
up of 701 days, providing 77,369 patient­days of exposure. 
Eligible patients had hyponatremia, finished SALT­1 and 
SALT­2 studies and wanted to continue tolvaptan therapy. 
Mean serum Na
+ of patients increased from 130.8 mEq/
L at baseline to more than 135 mEq/L during the study du­
ration (P < 0.001). Serum Na
+ in most patients of SIADH 
and heart failure was relatively well maintained at > 135 
mEq/L compared to patients with liver cirrhosis. The most 
common adverse effects were pollakiuria, thirst, dry mouth, 
and polyuria. Six patients withdrew due to drug­related 
adverse effects including severe ventricular tachycardia, 
severe irritability, mild serum sodium increase, mild anorexia, 
severe azotemia, and moderate pruritus. Rapid correction 
of serum sodium (> 1 mEq/L/hr) occurred in 5 patients. 
Hypernatremia (> 145 mEq/L) was observed in one 
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could maintain increased serum Na
+ and also could have a 
modest safety margin in chronic hyponatremia.
The Efficacy of Vasopressin Antagonism in Heart Failure 
Outcome Study With Tolvaptan (EVEREST) trials was 2 
multicenter, randomized, double­blind, placebo­controlled 
studies that evaluated the effects of tolvaptan in patients 
hospitalized with heart failure (HF)
18­20). In total, 4,133 pa­
tients were enrolled and randomized to receive tolvaptan 
(30 mg/day) or placebo group, both groups were allowed 
the standard HF therapy, within 48 hours of admission. The 
mean follow­up time was 9.9 months. The withdrawal rate 
and adverse events (predominantly due to dry mouth and 
thirst) in both groups were similar. Rapid improvement of 
signs and symptoms was seen in the tolvaptan group without 
serious adverse events. However, there was no difference in 
the primary endpoints of all causes of mor  tality, the composite 
of cardiovascular death and HF hospi  talization, or overall 
quality of life scores between the groups. Therefore, in HF 
patients, tolvaptan could not be initial standard therapy 
because of the evidence seen from EVEREST. Tolvaptan 
has not received approval from the United States Food and 
Drug Administration for this indication.
3. Indications, Dosing, and Administration
Tolvaptan is indicated for patients with clinically significant 
euvolemic or hypervolemic hyponatremia defined as Na
+ 
< 125 mEq/L and also indicated for mild hyponatremia (Na
+ 
< 125–135 mEq/L) in symptomatic patients, including 
patients with heart failure, cirrhosis, and SIADH that has 
resisted conventional therapy in the U.S.
13). However, in the 
European Union (EU), tolvaptan is approved for use in adults 
with hyponatraemia secondary to SIADH. Tolvaptan 
should not be used in patients requiring intervention to 
rapidly correct serum Na
+ to prevent or treat neurologic 
symptoms. The initiation of tolvaptan should only occur in 
a hospital setting to allow for monitoring of the therapeutic 
response and to avoid rapid correction of hyponatremia. 
The usual initial dose of tolvaptan is 15 mg orally once daily 
without regard to meals. Dose adjustments can be made 
after at least 24 hours, up to a maximum of 60 mg daily. 
Fluid restriction is not advised during the first 24 hours of 
therapy with the drug. Dosage adjustment according to 
age, gender, race, cardiac, mild­to­severe renal or hepatic 
function is not needed. Tolvaptan has not been evaluated 
in patients with a creatinine clearance 10 mL/min or in 
patients undergoing dialysis. However, no benefit can be 
expected in anuric patients
13).
4. Contraindication and Precautions
Tolvaptan, in patients with a need to rapidly correct serum 
Na
+, with an inability to sense thirst or appropriately res­
pond to thirst, and hypovolemic hyponatremia, should 
be contraindicated
13). Anuric patients have no clinical 
benefit of tolvaptan. The physician should take caution to 
avoid too rapid correction of serum Na
+ that may cause 
serious neurologic sequelae. Gastrointestinal bleeding 
more frequently occurs in liver cirrhosis patients receiving 
tolvaptan than in patients with placebo (10% vs. 2%)
13). 
Common adverse events of tolvaptan, defined as a 5% greater 
incidence than placebo, were thirst, dry mouth, asthenia, 
constipation, and pollakiuria
13).
5. Drug Interactions
Tolvaptan is metabolized via CYP3A4. While CYP3A4 
inducers, such as rifampin, decrease plasma concentrations 
of tolvaptan by 85%, strong inhibitors of CYP3A4, such 
as ketoconazole, clarithromycin, cyclosporine, tacrolimus, 
fluoxetine, amiodarone, cimetidine, and midazolam, increase 
plasma concentrations
13­15).
Conclusions
Through the SALT­1,­2, EVEREST, and SALTWATER 
studies, tolvaptan shows significant evidence that 1) it 
improves serum Na
+ levels patients with euvolaemic or hy­
pervolemic hyponatremia related with heart failure, cirrhosis 
or SIADH, 2) it has acceptable safety and tolerability for 54      Yi JH et al. • V2 Receptor Antagonist; Tolvaptan
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long­term usage in chronic hyponatremia, and 3) the bene­
ficial effects on serum Na
+ occurred in patients with both 
mild and marked hyponatraemia. However, an initiation 
of tolvaptan treatment should be performed in the hospital 
setting because physicians must closely check the changes of 
serum Na
+ during the dosage­titration phase. Tolvaptan, in 
Korea, is soon coming to the market. We hope that this article 
will assist in the understanding of tolvaptan and hope that 
this article may provide light on the subject.
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